🔗 Share this article Patients Stopping Weight-Loss Injections Put On Weight Four Times Faster Compared to Those on Conventional Diets Obesity treatment involves ongoing approaches. A recent study suggests that individuals who discontinue new GLP-1 drugs like Mounjaro or Wegovy may regain lost weight much more quickly than those who stop traditional diet and exercise plans. Findings released in a leading health publication points out that while overweight people can lose a large proportion of their body weight while on the medication, the weight returns at an estimated rate of 0.8 kg per month upon discontinuation. "Individuals purchasing such treatments should be aware of the potential of quick weight regain when the medication concludes," stated expert Dr. Susan Jebb. This pace of recovery implies a reversion to pre-treatment weight in about 18 months. Analyzing Therapies The analysis, which reviewed dozens of trials involving thousands of participants, contrasted the results of these new drugs with conventional dieting. Scientists emphasize that individuals who shed pounds through lifestyle changes alone typically experience a more gradual creep back—around 100 grams monthly—once they finish. Understanding the Fast Rebound Experts propose the mode of action of the drugs is key to understanding the amplified regain. GLP-1 drugs imitate a body's own chemical called glucagon-like peptide-1, which helps regulate feelings of fullness. "Sustained high doses of the hormone concentrations far above than normal could lead to the body to generate a reduced amount of its endogenous hormone, and may also reduce sensitivity to its actions," explained Dr. Adam Collins, a dietetics researcher. "Discontinuation of this hormone supplement results in appetite is uncontrolled, making excessive eating far more likely." An Ongoing Condition? Medical guidelines suggest the jabs for people with weight-linked medical conditions, accompanied by prescribed diet and exercise modifications. A number of clinicians contend that, due to the likelihood of weight regain, the therapy might need to be life-long. This view is echoed by pharmaceutical companies, who say that the results "underscore the long-term nature of excess weight," akin to managing diseases like diabetes. Patient Experiences Individuals who have stopped the medication explain a sudden resurgence of cravings. "It felt as if something flipping and you become starving," described one woman. The struggle is exacerbated if patients have not established permanent dietary or behavioural modifications during treatment. Widespread Interest Figures indicate that millions of adults in the UK have used these injections in the last 12 months, with desire continuing to grow. Use is higher among females compared to males. The middle-aged demographic shows the highest usage rates. Many access the drugs through private prescriptions rather than the NHS. Ultimately, researchers caution that while the jabs are effective agents for weight loss, they are not a permanent cure and maintained weight loss likely depends on ongoing lifestyle management.
Obesity treatment involves ongoing approaches. A recent study suggests that individuals who discontinue new GLP-1 drugs like Mounjaro or Wegovy may regain lost weight much more quickly than those who stop traditional diet and exercise plans. Findings released in a leading health publication points out that while overweight people can lose a large proportion of their body weight while on the medication, the weight returns at an estimated rate of 0.8 kg per month upon discontinuation. "Individuals purchasing such treatments should be aware of the potential of quick weight regain when the medication concludes," stated expert Dr. Susan Jebb. This pace of recovery implies a reversion to pre-treatment weight in about 18 months. Analyzing Therapies The analysis, which reviewed dozens of trials involving thousands of participants, contrasted the results of these new drugs with conventional dieting. Scientists emphasize that individuals who shed pounds through lifestyle changes alone typically experience a more gradual creep back—around 100 grams monthly—once they finish. Understanding the Fast Rebound Experts propose the mode of action of the drugs is key to understanding the amplified regain. GLP-1 drugs imitate a body's own chemical called glucagon-like peptide-1, which helps regulate feelings of fullness. "Sustained high doses of the hormone concentrations far above than normal could lead to the body to generate a reduced amount of its endogenous hormone, and may also reduce sensitivity to its actions," explained Dr. Adam Collins, a dietetics researcher. "Discontinuation of this hormone supplement results in appetite is uncontrolled, making excessive eating far more likely." An Ongoing Condition? Medical guidelines suggest the jabs for people with weight-linked medical conditions, accompanied by prescribed diet and exercise modifications. A number of clinicians contend that, due to the likelihood of weight regain, the therapy might need to be life-long. This view is echoed by pharmaceutical companies, who say that the results "underscore the long-term nature of excess weight," akin to managing diseases like diabetes. Patient Experiences Individuals who have stopped the medication explain a sudden resurgence of cravings. "It felt as if something flipping and you become starving," described one woman. The struggle is exacerbated if patients have not established permanent dietary or behavioural modifications during treatment. Widespread Interest Figures indicate that millions of adults in the UK have used these injections in the last 12 months, with desire continuing to grow. Use is higher among females compared to males. The middle-aged demographic shows the highest usage rates. Many access the drugs through private prescriptions rather than the NHS. Ultimately, researchers caution that while the jabs are effective agents for weight loss, they are not a permanent cure and maintained weight loss likely depends on ongoing lifestyle management.